Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk?
Author:
Affiliation:
1. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine
Link
http://academic.oup.com/eurheartj/article-pdf/42/39/4049/40655347/ehab602.pdf
Reference17 articles.
1. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis;Fowkes;Lancet,2013
2. REACH registry investigators. One-year costs associated with cardiovascular disease in Canada: insights from the REduction of Atherothrombosis for Continued Health (REACH) registry;Smolderen;Can J Cardiol,2010
3. Current and emerging drug treatment strategies for peripheral arterial disease;Essa;Expert Opin Pharmacother,2020
4. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004;Pande;Circulation,2011
5. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS);Aboyans;Eur Heart J,2018
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. RIvaroxaban and VAscular Surgery (RIVAS): insights from a multicenter, worldwide web-based survey;International Angiology;2024-05
2. Thrombotic and bleeding complications during antithrombotic treatment: the need for new therapeutic targets;European Heart Journal;2023-05-21
3. The key role of trials in cardiovascular medicine: challenges and opportunities;European Heart Journal;2023-03-14
4. Focus on trials: dementia, lipids, thrombosis, and heart failure;European Heart Journal;2022-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3